Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial
- 1 October 2004
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 364 (9441), 1244-1251
- https://doi.org/10.1016/s0140-6736(04)17141-9
Abstract
A WHO-recommended 8-month regimen based on ethambutol and isoniazid was evaluated in a randomised clinical trial against a 6-month standard regimen.1355 patients with newly diagnosed smear-positive pulmonary tuberculosis were randomly assigned one of three regimens: daily ethambutol, isoniazid, rifampicin, and pyrazinamide for 2 months, followed by ethambutol and isoniazid for 6 months (2EHRZ/6HE); the same drugs but given three times weekly in the initial intensive phase (2[EHRZ]3/6HE); or the same initial intensive phase as the first regimen, followed by 4 months of daily rifampicin and isoniazid (2EHRZ/4HR). Follow-up was to 30 months after the start of chemotherapy. Sputum was regularly examined by microscopy and culture. Unfavourable outcome was defined as failure during treatment or relapse afterwards. Analyses were by intention to treat.At 2 months, a significantly higher proportion of patients assigned the daily intensive phase than of those assigned the three-times-weekly regimen were culture negative (700/828 [85%] vs 333/433 [77%], p=0.001). 12 months after the end of chemotherapy, the proportions of unfavourable outcomes were 36 of 346 (10%) with 2EHRZ/6HE, 48 of 351 (14%) with 2(EHRZ)3/6HE, and 17 of 347 (5%) with 2EHRZ/4HR. Both 8-month regimens were significantly inferior to the control 6-month standard regimen (difference between control and 2EHRZ/6HE 5.5% [95% CI 1.6 to 9.4]; between control and 2(EHRZ)3/6HE 8.8% [4.5 to 13.0]). Adverse effects leading to interruption of treatment for 7 days or longer occurred in 28 patients (12 2EHRZ/6HE, five 2[EHRZ]3/6HE, 11 2EHRZ/4HR).The results of this study must be taken into account in recommendations on management of new cases of smear-positive tuberculosis.This publication has 8 references indexed in Scilit:
- Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 DaysAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosisThe Lancet, 1991
- Five-Year Follow-Up of a Controlled Trial of Five 6-Month Regimens of Chemotherapy for Pulmonary TuberculosisAmerican Review of Respiratory Disease, 1987
- Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: Final reportTubercle, 1986
- A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis Final report: Results during the 36 months after the end of chemotherapy and beyondRespiratory Medicine, 1984
- Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis second report: the results up to 24 monthsTubercle, 1982
- Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis Second reportTubercle, 1980
- Bactericidal Activity of Streptomycin, Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Alone and In Combination Against Mycobacterium Tuberculosis1American Review of Respiratory Disease, 1977